Virpax Pharmaceuticals, Inc. Business Operations Contracts & Agreements
23 Contracts & Agreements
- Agency Agreements (8 contracts)
- Collaboration Agreements (7)
- Development Agreements (4)
- Indemnification Agreements (2)
- Services Agreements (1)
- Settlement Agreements (1)
- Form of Investor Relations Agreement, by and between the Company and IR Agency LLC (Filed With SEC on January 15, 2025)
- Form of Placement Agency Agreement (Filed With SEC on January 15, 2025)
- Form of Investor Relations Agreement, dated November 12, 2024, between the Company and IR Agency LLC (Filed With SEC on November 15, 2024)
- Form of Placement Agency Agreement (Filed With SEC on November 15, 2024)
- Form of Placement Agency Agreement (Filed With SEC on October 18, 2024)
- Form of Placement Agency Agreement (Filed With SEC on August 13, 2024)
- Placement Agency Agreement, dated as of May 14, 2024, by and between Virpax Pharmaceuticals, Inc. and A.G.P./Alliance Global Partners, as placement agent (Filed With SEC on May 17, 2024)
- Form of Placement Agency Agreement (Filed With SEC on April 18, 2024)
- Indemnification Agreement, dated March 25, 2024, by and between Virpax Pharmaceuticals, Inc. and Vinay Shah (Filed With SEC on March 26, 2024)
- Settlement Agreement and Mutual Release between Virpax Pharmaceuticals, Inc. and Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals Inc (Filed With SEC on March 1, 2024)
- Amended and Restated Collaboration and License Agreement between Nanomerics Ltd. and Virpax Pharmaceuticals, Inc., dated as of March 9, 2022 (Filed With SEC on March 31, 2022)
- Agreement for Rendering of Research Services between Virpax Pharmaceuticals, Inc. and Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd., dated June... (Filed With SEC on September 9, 2021)
- Agreement for Rendering of Research Services between LipoCureRx, Ltd. and Virpax Pharmaceuticals, Inc., dated June 29, 2021 (Filed With SEC on September 9, 2021)
- Amendment to the Collaboration and License Agreement dated April 11, 2019, as amended, between Nanomerics Ltd. and Virpax Pharmaceuticals Inc., dated May 5, 2021 (Filed With SEC on August 10, 2021)
- Amendment to the Collaboration and License Agreement dated April 11, 2019, as amended, between Nanomerics Ltd. and Virpax Pharmaceuticals, Inc., dated April 6, 2021 (Filed With SEC on August 10, 2021)
- Amendment No. 1 to the Collaboration and License Agreement between Nanomerics Ltd. and Virpax Pharmaceuticals, Inc., dated as of December 31, 2020 (Filed With SEC on January 8, 2021)
- Collaboration and License Agreement between Nanomerics Ltd. and Virpax Pharmaceuticals, Inc., dated August 7, 2020 (Filed With SEC on November 20, 2020)
- Agreement for the Rendering of Research Services by and between Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. and Virpax Pharmaceuticals, Inc.,... (Filed With SEC on November 20, 2020)
- Agreement for the Rendering of Research Services by and between Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. and Virpax Pharmaceuticals, Inc.,... (Filed With SEC on November 20, 2020)
- Amendment to the Collaboration and License Agreement by and between Nanomerics Ltd. and Virpax Pharmaceuticals, Inc., dated as of December 30, 2019 (Filed With SEC on November 20, 2020)
- Collaboration and License Agreement by and between Nanomerics Ltd. and Virpax Pharmaceuticals, Inc., dated as of April 11, 2019 (Filed With SEC on November 20, 2020)
- Form of Indemnification Agreement entered into by Virpax Pharmaceuticals, Inc. with its Officers and Directors (Filed With SEC on November 20, 2020)
- Cooperative Research and Development Agreement, dated August 25, 2020, between the U.S. Department of Health and Human Services, as represented by National Center for Advancing... (Filed With SEC on October 9, 2020)
